Nothing Special   »   [go: up one dir, main page]

ES2061670T3 - Cicloalcanoles substituidos. - Google Patents

Cicloalcanoles substituidos.

Info

Publication number
ES2061670T3
ES2061670T3 ES88308565T ES88308565T ES2061670T3 ES 2061670 T3 ES2061670 T3 ES 2061670T3 ES 88308565 T ES88308565 T ES 88308565T ES 88308565 T ES88308565 T ES 88308565T ES 2061670 T3 ES2061670 T3 ES 2061670T3
Authority
ES
Spain
Prior art keywords
halo
integers
alkyl
hydrogen
cycloalcanols
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES88308565T
Other languages
English (en)
Inventor
George Edward Morris Husbands
Gary Paul Stack
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wyeth LLC
Original Assignee
American Home Products Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Home Products Corp filed Critical American Home Products Corp
Application granted granted Critical
Publication of ES2061670T3 publication Critical patent/ES2061670T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/04Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/26Psychostimulants, e.g. nicotine, cocaine
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D295/00Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

COMPUESTOS DE FORMULA(I) EN LA QUE M ES 1, 2 O 3; N ESW 0, 1 O 2; R1 Y R2 SON INDEPENDIENTEMENTE H, HIDROXILO, ALQUILO, ALCOXILO, ALCANOYLOXI, TRIFLUOROMETILO, HALO O CUANDO LOS TAMAÑOS JUNTOS 3,4 - METILENEDIOXI; R3 ES ALQUILO; DONDE R4 Y R5 SON INDEPENDIENTEMENTE H, HIDROXILO, ALQUILO, ALCOXI, ALCANOILOXI, HALO O TRIFLUOROMETILO; Y R6 ES H O HALO; O LAS SALES DE ESTA ACEPTABLES FARMACEUTICAMENTE, SON UTILES EN EL TRATAMIENTO DE LOS DESORDENES PSIQUIATRICOS.
ES88308565T 1987-09-30 1988-09-16 Cicloalcanoles substituidos. Expired - Lifetime ES2061670T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/102,695 US4826844A (en) 1987-09-30 1987-09-30 Substituted 1-(aralkyl-piperazinoalkyl) cycloalkanols

Publications (1)

Publication Number Publication Date
ES2061670T3 true ES2061670T3 (es) 1994-12-16

Family

ID=22291200

Family Applications (1)

Application Number Title Priority Date Filing Date
ES88308565T Expired - Lifetime ES2061670T3 (es) 1987-09-30 1988-09-16 Cicloalcanoles substituidos.

Country Status (12)

Country Link
US (1) US4826844A (es)
EP (1) EP0310268B1 (es)
JP (1) JPH01121281A (es)
KR (1) KR890005069A (es)
AT (1) ATE101140T1 (es)
AU (1) AU617117B2 (es)
CA (1) CA1301757C (es)
DE (1) DE3887614T2 (es)
ES (1) ES2061670T3 (es)
GB (1) GB2210366B (es)
IE (1) IE60916B1 (es)
ZA (1) ZA886798B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506270A (en) * 1995-01-30 1996-04-09 American Home Products Corporation Venlafaxine in the treatment of hypothalamic amenorrhea in non-depressed women
SE9504661D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9504662D0 (sv) * 1995-12-22 1995-12-22 Astra Pharma Inc New compounds
SE9904673D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE9904674D0 (sv) 1999-12-20 1999-12-20 Astra Pharma Inc Novel compounds
SE0001209D0 (sv) 2000-04-04 2000-04-04 Astrazeneca Canada Inc Novel compounds
KR100885100B1 (ko) 2001-05-18 2009-02-20 아스트라제네카 아베 4(페닐-피페라지닐-메틸)벤즈아미드 유도체 및 통증,불안증 또는 위장관 장애 치료를 위한 이들의 용도
DE10161644A1 (de) * 2001-12-14 2003-06-26 Gruenenthal Gmbh N,N'-disubstituierte Piperazin-Verbindungen
WO2003053927A1 (fr) * 2001-12-21 2003-07-03 Taisho Pharmaceutical Co.,Ltd. Dérivé de piperazine
US20040180879A1 (en) * 2002-10-15 2004-09-16 Deecher Darlene Coleman Novel method of treating vasomotor symptoms
US20040152710A1 (en) * 2002-10-15 2004-08-05 Deecher Darlene Coleman Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
US7345096B2 (en) * 2002-10-15 2008-03-18 Wyeth Use of norepinephrine reuptake modulators for preventing and treating vasomotor symptoms
SE0203302D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203300D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
SE0203303D0 (sv) 2002-11-07 2002-11-07 Astrazeneca Ab Novel Compounds
US7491723B2 (en) * 2003-10-14 2009-02-17 Wyeth Alkanol and cycloalkanol-amine derivatives and methods of their use
US7524846B2 (en) * 2003-10-14 2009-04-28 Wyeth Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use
US7402698B2 (en) * 2003-10-14 2008-07-22 Wyeth Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use
US7365076B2 (en) * 2003-10-14 2008-04-29 Wyeth Substituted aryl cycloalkanol derivatives and methods of their use
US7531543B2 (en) * 2003-10-14 2009-05-12 Wyeth Phenylpiperazine cycloalkanol derivatives and methods of their use
US20050130987A1 (en) * 2003-10-14 2005-06-16 Wyeth Methods of treating vasomotor symptoms
US7419980B2 (en) * 2003-10-14 2008-09-02 Wyeth Fused-aryl and heteroaryl derivatives and methods of their use
US7550485B2 (en) * 2003-10-14 2009-06-23 Wyeth Substituted N-heterocycle derivatives and methods of their use
US20050207983A1 (en) * 2004-03-05 2005-09-22 Pulmatrix, Inc. Formulations decreasing particle exhalation
US7517899B2 (en) * 2004-03-30 2009-04-14 Wyeth Phenylaminopropanol derivatives and methods of their use
US7414052B2 (en) * 2004-03-30 2008-08-19 Wyeth Phenylaminopropanol derivatives and methods of their use
KR101234421B1 (ko) 2004-08-02 2013-02-18 아스트라제네카 아베 디아릴메틸 피페라진 유도체, 이의 제조 방법 및 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH351273A (fr) * 1954-11-12 1961-01-15 Abbott Lab Procédé de préparation de sels d'ammonium quaternaire
US2971955A (en) * 1958-12-29 1961-02-14 Abbott Lab Cyclohexylcarbinol derivatives of piperazine
US4163849A (en) * 1978-03-17 1979-08-07 Merck & Co., Inc. Piperazinylpyrazines
US4535186A (en) * 1983-04-19 1985-08-13 American Home Products Corporation 2-Phenyl-2-(1-hydroxycycloalkyl or 1-hydroxycycloalk-2-enyl)ethylamine derivatives
FR2559765B1 (fr) * 1984-02-16 1986-06-13 Rhone Poulenc Sante Nouveaux derives de la phenyl-3 propene-2 amine, leur preparation et les medicaments qui les contiennent
US4605655A (en) * 1984-03-06 1986-08-12 Bristol-Myers Company Antipsychotic 1-fluorophenylbutyl-4-(2-pyrimidinyl)piperazine derivatives
US4745191A (en) * 1987-09-30 1988-05-17 American Home Products Corporation 1-((A-substituted phenyl-ω-substituted piperazinyl)alkenyl) cyclohexanol

Also Published As

Publication number Publication date
EP0310268A2 (en) 1989-04-05
ZA886798B (en) 1990-05-30
GB8821758D0 (en) 1988-10-19
ATE101140T1 (de) 1994-02-15
AU617117B2 (en) 1991-11-21
AU2215588A (en) 1989-04-06
DE3887614D1 (de) 1994-03-17
IE882710L (en) 1989-03-30
GB2210366B (en) 1991-05-29
US4826844A (en) 1989-05-02
KR890005069A (ko) 1989-04-11
IE60916B1 (en) 1994-08-24
GB2210366A (en) 1989-06-07
EP0310268B1 (en) 1994-02-02
JPH01121281A (ja) 1989-05-12
DE3887614T2 (de) 1994-05-11
EP0310268A3 (en) 1990-05-23
CA1301757C (en) 1992-05-26

Similar Documents

Publication Publication Date Title
ES2061670T3 (es) Cicloalcanoles substituidos.
PL292101A1 (en) Method of obtaining novel derivatives of cyclopentylpurine and cyclopentylpyrimidine
ZA911502B (en) A pharmaceutical solution
ZA9710292B (en) Atherosclerosis treatment
ES8604128A1 (es) Un procedimiento para la preparacion de nuevos derivados de bencenosulfonamida
HUT45984A (en) Process for production of quinoline-derivatives and of their medically acceptable acid-additioned salts
GR3005990T3 (es)
IL118368A0 (en) N-oxide heteroaroyl derivatives
HUT48209A (en) Process for producing heterocyclic oxo compounds comprising substituted amino group and having antiallergic and antiinflammatory action
FI875145A0 (fi) Kondenserade heterocykliska tetrahydroaminokinoliner och beslaektade foereningar, en metod foer deras framstaellning och deras anvaendning som mediciner.
GB8706662D0 (en) Anti-arrhythmia agents
DE3572814D1 (en) 1, 3-benzoxathiole derivatives, their use and their preparation
FI901277A0 (fi) 2,5,6,7-tetranor-4,8-inter-m-fenylen pg1z-derivativ.
ES2097435T3 (es) Derivados de 2,16-bispiperidinilandrostano monocuaternarios.
DK0784973T3 (da) Quinoxalinderivater til behandling af tinnitus
GR3004095T3 (es)
IL75430A (en) Pineapple ketone carbonate derivatives and their use as flavoring agents
ES2093051T3 (es) Purinil- y pirimidil-tetrahidrofuranos.
ES2004215A6 (es) Procedimiento para preparar quinazolinas tetraciclicas
DE3867494D1 (de) Fluor enthaltende vitamin-d2-derivate.
ATE81465T1 (de) Verwendung von 2-oxo-imidazolidin-derivaten zur behandlung von nierenkrankheiten.
GB8600879D0 (en) Pregnane derivatives

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 310268

Country of ref document: ES